Disease or Syndrome – Page 15

Ono Pharmaceutical and Jorna Therapeutics Partner for AI-Driven RNA Editing Therapies

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Dosage Forms, Drug Discovery, Jorna, RNA

Ono Pharmaceutical, Jorna Therapeutics, AI Drug Discovery, RNA Editing Therapies

FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD

2 months ago talkbio0Tagged Age related macular degeneration, Diabetic Retinopathy, dosing, Extension, Eylea HD, Interval, Regeneron, Rejection, United States Food and Drug Administration

United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

2 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

2 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

FDA clears its first prescription migraine app, from Click Therapeutics

2 months ago talkbio0Tagged click, Click Therapeutics, CT-132, first, Migraine Disorders, United States Food and Drug Administration

United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

2 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

HHS Terminates Funding for GeoVax’s Next-Generation COVID-19 Vaccine: Impacts and Developments

2 months ago talkbio0Tagged BARDA, CHARGE Syndrome, Clinical Trials, COVID19 (disease), development aspects, GeoVax, Immunocompromised Host, pandemic preparedness, Project NextGen, Termination - Inactive Reason Code, Vaccines

GeoVax, HHS, BARDA, Project NextGen, COVID-19 vaccine, GEO-CM04S1, clinical trials, funding termination, immunocompromised, vaccine development, pandemic preparedness

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

2 months ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Glycomine raises $115M to see if it can treat rare glycosylation disorder

2 months ago talkbio0Tagged Congenital disorder of glycosylation type 1A, GLM101, Glycomine, Infrequent

Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A

Novartis Halts Phase 2 Osteoarthritis Study of ADAMTS-5 Inhibitor Due to Lack of Pain Relief

2 months ago talkbio0Tagged ADAMTS-5, cartilage degradation, Clinical Trial Termination, Degenerative polyarthritis, Drug Development, Inhibitor, Knee pain, M6495, Novartis, Pain, QUC398

Novartis, phase 2 trial, osteoarthritis, knee pain, ADAMTS-5 inhibitor, QUC398, M6495, clinical trial termination, pain relief, cartilage degradation, drug development